First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Miami, Miami, Florida +30 locations
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Register for Updates
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877
Recruiting
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +109 locations
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
NCT06846554
Recruiting
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults wi... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/10/2025
Locations: Hammersmith/Imperial Hospital, London, Not set
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859
Recruiting
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-F... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: GSK Investigational Site, Sacramento, California +50 locations
Conditions: Hepatitis B
Register for Updates
International Validation of Two Non-motor Scales in PD (NFS and SPARK)
NCT04366804
Recruiting
The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD).
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
04/09/2025
Locations: Centre hospitalier régional universitaire de Besançon, Besançon, Not set +7 locations
Conditions: Parkinson's Disease, Non-motor Symptoms
Register for Updates
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Stanford Healthcare, Palo Alto, California +30 locations
Conditions: Alcohol Associated Hepatitis
Register for Updates
Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)
NCT06440629
Recruiting
The goal of this clinical trial is to compare therapeutic drug monitoring (TDM) versus Standard of care in patients with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor (adalimumab). The main question it aims to answer is: Is TDM superior to standard of care in order to maintain sustained disease control without flares? Participants will be followed with blood sampling every second month, measuring serum drug levels and anti-drug antibodies of the TNFi. In the... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
04/09/2025
Locations: Medical University Vienna, Vienna, Not set +20 locations
Conditions: Rheumatoid Arthritis
Register for Updates
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06174987
Recruiting
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Miami Cancer Institute, Miami, Florida +27 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Avapritinib Rollover Study
NCT06748001
Recruiting
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
Gender:
ALL
Ages:
All
Trial Updated:
04/09/2025
Locations: Universitair Ziekenhuis Antwerpen (UZA), Edegem, Not set +4 locations
Conditions: Mastocytosis, Systemic
Register for Updates
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
NCT00198068
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/09/2025
Locations: Northwestern University, Chicago, Illinois +9 locations
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Register for Updates
REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
NCT06922175
Recruiting
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg, Freiburg im Breisgau, Not set +9 locations
Conditions: Epilepsy With Uncontrolled Focal-onset Seizures
Register for Updates
ID93/GLA-SE Vaccination + BCG Challenge
NCT06670755
Recruiting
The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2. Provide preliminary immunogenicity data of this novel TB vaccine (ID93/GLA-SE). This clinical trial will apply an aerosol BCG challenge model involving 48 participants - 24 historically BCG-vaccinated volunteers and 24 BCG-naïve volunteers. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial sam... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/09/2025
Locations: Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire
Conditions: Tuberculosis
Register for Updates